Changing Hemophilia

Novo Nordisk is committed to Changing Hemophilia, working towards a future where all people living with hemophilia, with or without inhibitors, have the opportunity to lead the life they desire.

Changing Hemophilia represents Novo Nordisk’s commitment to the whole of the hemophilia and rare bleeding disorder community. Driven by a vision and core ambitions our commitment links together all the company’s activities, from development of new treatments to support of community projects, which are aimed at improving the lives of people with hemophilia and allied bleeding disorders.


The Changing Hemophilia programme has three overarching ambitions, to:

  • Strengthen understanding of hemophilia in the broader society
  • Improve access to diagnosis, care and treatment
  • Advance treatment and care through innovation

Read more about our ambitions here